JIC
IRMD icon

Johnson Investment Counsel’s iRadimed IRMD Stock Holding History

Johnson Investment Counsel’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Sell
20,439
-5,403
-21% -$540K 0.02% 331
2025
Q4 		$2.51M Hold
25,842
– – 0.02% 273
2025
Q3 		$1.84M Buy
25,842
+187
+0.7% +$12.5K 0.02% 322
2025
Q2 		$1.53M Buy
+25,655
New +$1.41M 0.01% 347

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Johnson Investment Counsel's IRMD Position: Q1 2026 in Review

Johnson Investment Counsel reduced its iRadimed (IRMD) stake by 21% in Q1 2026, selling an estimated $540K and leaving 20,439 shares worth $1.97M. The position accounts for 0.02% of the portfolio, ranked #331.

Johnson Investment Counsel first reported a position in IRMD in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.51M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Johnson Investment Counsel held 20,439 shares of iRadimed worth $1.97M as of Q1 2026.
  • Johnson Investment Counsel sold 5,403 iRadimed shares in Q1 2026, an estimated $540K.
  • iRadimed made up 0.02% of Johnson Investment Counsel's portfolio in Q1 2026, its #331 holding.
  • Johnson Investment Counsel first reported a position in iRadimed in Q2 2025 and has held it in 4 quarters since.
  • Johnson Investment Counsel's iRadimed position peaked at $2.51M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Johnson Investment Counsel's 13F filing for Q1 2026, filed 4 May 2026.